Vaxart, Inc. (VXRT) stock
VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$0.48+0.02 (+5.04%)
Close on Oct 19, 2026Market cap $115.15MP/E 3.2Yield –
Vaxart net income
Net income is the profit left for shareholders after every expense, interest and tax.
Vaxart's net income for the twelve months ending Jun 30, 2026 was $38.59M. For fiscal 2025 it was $16.33M. The highest annual figure on record is $16.33M in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.33M | – |
| FY2024 | Dec 31, 2024 | -$66.95M | – |
| FY2023 | Dec 31, 2023 | -$82.47M | – |
| FY2022 | Dec 31, 2022 | -$107.76M | – |
| FY2021 | Dec 31, 2021 | -$70.47M | – |
| FY2020 | Dec 31, 2020 | -$32.22M | – |
| FY2019 | Dec 31, 2019 | -$18.65M | – |
| FY2018 | Dec 31, 2018 | -$18.01M | – |
| FY2016 | Jun 30, 2016 | -$25.40M | – |
| FY2015 | Jun 30, 2015 | -$19.10M | – |
| FY2014 | Jun 30, 2014 | -$11.00M | – |
| FY2013 | Jun 30, 2013 | -$8.90M | – |
| FY2012 | Jun 30, 2012 | -$19.20M | – |
| FY2009 | Dec 26, 2009 | -$18.73M | – |
Quarterly net income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$13.49M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $5.18M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $55.05M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$8.14M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$14.99M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$15.59M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$11.99M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$14.08M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$16.47M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$24.42M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$17.38M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$17.40M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$22.55M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$25.14M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$23.92M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$29.31M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$29.43M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$25.10M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$20.76M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$17.58M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$16.12M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$16.01M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$13.86M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$8.09M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$8.98M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$1.30M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$6.41M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$5.26M | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$5.64M | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$1.34M | -157.9% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$4.90M | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$6.55M | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$8.87M | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $2.31M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$7.10M | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$5.20M | -533.3% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -$6.50M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | -$6.60M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -$19.90M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $1.20M | – |
See a number that looks wrong?